Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERTIFY: Certolizumab for unexplained recurrent implantation failure
2024-511869-11-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Recurrent Implantation Failure (RIF) and female infertility comparing Certolizumab (Cimzia) with Placebo (sodium chloride) (2 arms). Primary endpoint: Clinical pregnancy rate. Planned start Nov 2024; status: authorised.
02
Drugs
certolizumab pegol
03
Conditions
Recurrent Implantation Failure (RIF)female infertility
Beyond the preview
Go deeper on 2024-511869-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511869-11-00.